US Capitol Capsule: Advance Science, Don't Pressure FDA On Approvals, Drug Chief Tells Advocates
This article was originally published in Scrip
Executive Summary
"Patient advocacy groups should be in the business of advocating for patients, not advocating for specific drugs or development programs," Janet Woodcock, director of the FDA's Center for Drug Evaluation and Research (CDER), insisted last week at the Biotechnology Industry Organization's 2015 Patient and Health Advocacy Summit in Washington.